MLTX
NASDAQ · Biotechnology
Moonlake Immunotherapeutics
$18.26
+0.23 (+1.28%)
Open$18.47
Previous Close$18.03
Day High$18.63
Day Low$17.92
52W High$62.75
52W Low$5.95
Volume—
Avg Volume802.9K
Market Cap1.54B
P/E Ratio—
EPS$-3.87
SectorBiotechnology
Analyst Ratings
Strong Buy
22 analysts
Price Target
-42.3% upside
Current
$18.26
$18.26
Target
$10.54
$10.54
$8.06
$10.54 avg
$16.98
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 207.37M | 195.61M | 178.47M |
| Net Income | -41,056,867 | -38,376,149 | -44,335,912 |
| Profit Margin | -19.8% | -19.6% | -24.8% |
| EBITDA | -81,449,014 | -69,654,675 | -60,804,840 |
| Free Cash Flow | -45,845,658 | -33,391,408 | -32,934,200 |
| Rev Growth | +19.2% | +9.7% | +1.7% |
| Debt/Equity | 0.11 | 0.10 | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |